Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Allergan, Inc.    AGN

No quotes available
-- USD   0.00%
09/27 TOBIRA THERAPEU : TBRA) Set to be Acquired by Allergan (AGN) as Ceni..
09/27 ALLERGAN : Receives FDA Approval to Market Natrelle Inspira Breast I..
09/26 ACQUISITION OF : TBRA) Under Investigation for Investors
SummaryQuotesNewsCalendarCompanyFinancials 
News SummaryMost relevantAll newsSector news 

Allergan, Inc. : Allergan : Studies Show Botox Treats Overactive Bladder

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/28/2012 | 03:54pm CEST

Allergan Inc. (AGN) filed applications with U.S. and European regulators for approval to sell Botox as a treatment for overactive bladder as two Phase III clinical trials showed the injectible neurotoxin significantly reduced urinary incontinence when compared with a placebo.

Botox is approved for both cosmetic use, such as fighting wrinkles, and for various medical issues, including urinary incontinence in patients with neurologic conditions such as spinal-cord injury and multiple sclerosis.

Allergan on Wednesday said Botox met the primary endpoints of significantly reducing urinary incontinence, or bladder leakage, episodes in patients who have an inadequate response to or are intolerant of an anticholinergic medication.

Based on the results, Allergan has submitted a supplemental biologics license application with the U.S. Food and Drug Administration and an application with European Regulatory authorities to approve the use of Botox by adult patients not managed by an anticholinergic treatment.

The drug maker has been expanding its pipeline of late, such as buying Vicept Therapeutics Inc., the developer of a cream to treat rosacea, and striking a deal with Map Pharmaceuticals Inc. (MAPP) to jointly promote Map's experimental migraine treatment Levadex.

Allergan reported last month its fourth-quarter earnings rose 6.3% as higher specialty pharmaceuticals sales contributed to a 7.1% revenue jump.

-By Melodie Warner, Dow Jones Newswires; 212-416-2283; melodie.warner@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ALLERGAN, INC.
09/27 TOBIRA THERAPEUTICS : TBRA) Set to be Acquired by Allergan (AGN) as Cenicriviroc..
09/27 ALLERGAN : Receives FDA Approval to Market Natrelle Inspira Breast Implants
09/26 ACQUISITION OF TOBIRA THERAPEUTICS I : TBRA) Under Investigation for Investors
09/25 5 TOP NASDAQ BIOTECH STOCKS : Tobira Therapeutics Gains 752 Percent
09/25 ALLERGAN : CEO of drugs giant blasts ‘egregious' price hikes
09/24 ALLERGAN : to buy three companies for combined $2.4 billion
09/24 ALLERGAN : CEO of drugmaker blasts 'egregious' price hikes Allergan boss says ph..
09/23 TWO SPECULATIVE NASH ALLOCATIONS POS : AGN)’s Tobira Therapeutics Inc (NAS..
09/23 ALLERGAN : to buy three companies for combined $2.4 billion
09/21 ALLERGAN PLC (NYSE : AGN) Buys Two Biotech Companies In One Day
More news
Sector news : Pharmaceuticals - NEC
02:40pDJGLAXOSMITHKLINE : Appoints New Consumer Healthcare Chief
10:26aDJNOVO NORDISK A/S : to Cut 1,000 Jobs Amid Growing Competition -- Update
09/28DJINTRA CELLULAR THERAPIES : Shares Plunge After Disappointing Drug Trial Results
09/28DJGLAXOSMITHKLINE : to Sell Remaining 6.2% Stake in Aspen Pharmacare
09/28 Monsanto ally Novozymes sees opportunity, risk in Bayer merger
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
2015 MANNKIND : A Head Pain Gain Or A Pocket-Book Drain?
2015 Tracking Dan Loeb's Third Point Portfolio - Q1 2015 Update
2015 Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q1 2015 Update
2015 Time Warner Is A Buy - Cramer's Lightning Round (5/21/15)
2015 Tracking John Paulson's Paulson & Company Portfolio - Q1 2015 Update
Advertisement
Income Statement Evolution
More Financials
Managers
NameTitle
Ambrose Robert Douglas Bailey Chairman & President
Scott M. Whitcup Chief Scientific Officer & Executive VP-Research
Raymond H. Diradoorian Executive VP-Global Technical Operations
Maria Teresa Hilado Director
Joann Bradley Investor Relations Contact
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ALLERGAN, INC.13.00%0
JOHNSON & JOHNSON16.23%326 636
ROCHE HOLDING LTD.-12.41%217 190
NOVARTIS AG-10.14%212 589
PFIZER INC.5.30%206 172
MERCK & CO., INC.19.84%175 038
More Results